Roche Obesity Shot Reduces Body Weight by 15.5% in Mid-Stage Trial
Product·1 article across 1 outlet
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Roche Holding AG’s experimental obesity shot enicepatide reduced both blood sugar and body weight in patients with type 2 diabetes who were overweight or obese in a mid-stage trial.
The trial demonstrated a significant reduction in body weight, achieving a decrease of 15.5% among participants.
Roche
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Roche Holding AG’s experimental obesity shot enicepatide reduced both blood sugar and body weight in patients with type 2 diabetes who were overweight or obese in a mid-stage trial.”
Bloomberg — Roche Obesity Shot Cuts Body Weight 15.5% in Mid-Stage Trial